The CVP – Strategy/Corp Development of Edwards Lifesciences (EW), Donald Bobo Unloaded 5,300 Shares; Profile of 13 Analysts Covering Trevena, Inc. (TRVN)

Trevena, Inc. (NASDAQ:TRVN) Logo

Among 14 analysts covering Trevena Inc (NASDAQ:TRVN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Trevena Inc had 23 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was initiated by Brean Capital on Monday, August 3 with “Buy”. The firm has “Outperform” rating by Oppenheimer given on Thursday, January 5. The rating was maintained by Roth Capital on Friday, July 21 with “Buy”. The firm earned “Buy” rating on Monday, June 19 by Aegis Capital. The stock of Trevena, Inc. (NASDAQ:TRVN) has “Outperform” rating given on Wednesday, February 22 by FBR Capital. The stock has “Outperform” rating by Cowen & Co on Tuesday, September 1. FBR Capital initiated Trevena, Inc. (NASDAQ:TRVN) rating on Tuesday, March 29. FBR Capital has “Outperform” rating and $16 target. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, February 23 report. H.C. Wainwright maintained the shares of TRVN in report on Friday, July 21 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Monday, January 9. See Trevena, Inc. (NASDAQ:TRVN) latest ratings:

16/10/2017 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $29.30 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 51.67 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on April, 24. They expect $1.10 EPS, up 17.02% or $0.16 from last year’s $0.94 per share. EW’s profit will be $231.03M for 31.71 P/E if the $1.10 EPS becomes a reality. After $0.94 actual EPS reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts 17.02% EPS growth.

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp has $195 highest and $86 lowest target. $133.78’s average target is -4.11% below currents $139.52 stock price. Edwards Lifesciences Corp had 108 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, September 5 by Jefferies. The stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Buy” rating by Jefferies on Thursday, June 29. RBC Capital Markets maintained Edwards Lifesciences Corporation (NYSE:EW) rating on Friday, September 1. RBC Capital Markets has “Buy” rating and $130.0 target. The firm earned “Outperform” rating on Wednesday, April 27 by Cowen & Co. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Friday, February 2 by RBC Capital Markets. BMO Capital Markets maintained it with “Buy” rating and $137.0 target in Thursday, December 7 report. Morgan Stanley maintained Edwards Lifesciences Corporation (NYSE:EW) on Friday, February 2 with “Overweight” rating. The firm earned “Buy” rating on Monday, September 4 by Canaccord Genuity. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, October 26. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, April 26.

Donald Bobo, the CVP – Strategy/Corp Development of Edwards Lifesciences Corp made deal for 5,300 shares with the average stock price of $138.6 in the Pinksheet-listed company, that are with a total value of $734,466 USD. This stocks unloading decreased his ownership of Edwards Lifesciences Corp to 0.05% stock market capitalization or 98,915 shares.

The stock increased 2.01% or $2.75 during the last trading session, reaching $139.52. About 1.49M shares traded or 13.34% up from the average. Edwards Lifesciences Corporation (NYSE:EW) has risen 44.06% since March 30, 2017 and is uptrending. It has outperformed by 32.51% the S&P500.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Chart